What to Look for in a CDMO

This article is the third part of our “Best Practices in the CDMO Selection Process” series, through which we intend to provide sound advice to agile biotech companies in identifying and selecting the right Contract Development and Manufacturing Organization (CDMO) for advancing the development of their product(s), in conjunction with successfully managing a chosen CDMO to meet the company’s expectations.

Publications
Published on:
September 8, 2022

In this article we will focus on the evaluation of a few identified CDMOs. There are several factors to consider and while some may be subjective to your company’s needs and culture, most should be quantifiable and tracked in a spreadsheet that lets you compare potential CDMOs in a like-for-like way. Let’s review the most important factors in creating a successful sponsor-CDMO relationship.

Overall, these attributes should illustrate whether a CDMO can deliver the quality and amount of product at the right cost."
Technology fit

The most important question to ask is whether a CDMO has the right technology for your product needs. The CDMO must be able to produce your product. If not, nothing else matters. To assess the CDMO’s technology capability, ask if they have the:

  • Required microbial and/or mammalian expression technology
  • Development expertise and resources to support production. This includes cell line, process, formulation, and/or analytical method development—tasks that are separate to the GMP tasks of master cell banking, drug substance, drug product, clinical labeling, and clinical packaging.
  • Available stainless steel and/or single use production systems required for products that include drug substance (DS). Other related questions to ask here are: Are you transferring an existing process from another facility? If so, does the production equipment match?
  • Production scale capabilities to match your product needs.
Project Management

Project management is a crucial service provided by a CDMO. Note whether their delivery dates are realistic and if the timeline fits your schedule. Also, during your CDMO visit, observe their communication style and staff culture. Make sure this complements your own company culture and style.

Location

Location is another important consideration. For non-clinical and early-stage clinical programs—where the CDMO has no experience with the product molecule—close communication between sponsor and CDMO is essential. Generally, a CDMO encounters fewer program issues when the sponsor is and remains engaged. Eventually, every project will require technical transfer. If a CDMO is technically competent with a strong track record of tested systems, they encounter fewer issues and often solve issues they do encounter on their own. This can make location less of a factor; however, you must assess your communication and collaboration needs as well as the impact distance may have.

Overall, these attributes should illustrate whether a CDMO can deliver the quality and amount of product at the right cost. A good CDMO will know its strengths and be willing to seek outside assistance for any present gaps. Ultimately, it is about managing risk, so weigh that against all other factors.

If you have decided to outsource your manufacturing and would like to identify the right CDMO for your project, we are here to assist. Our expert team has been helping companies choose the right CDMO for more than a decade – reach out to us to learn how we can support.

Related news

Publications January 18, 2023
The State of Biopharma Funding
We spoke with Joris Pezzini, Executive Vice President of Biopharma, Alira Health, during the J.P. Morgan Healthcare Conference in San Francisco, which brings together investors and(...)
Biopharma Biotech Funding Pharma
Events January 11, 2023
MD&M West 2023
Join our colleague Carlo Stimamiglio for his presentation “MedTech CDMO: Market and M&A Trends in 2023”, as he goes over key takeaways from our upcoming 2023 US MedTech CDMO Report.
CDMO MedTech
Publications December 6, 2022
Review of 2021-22 and 2023 Outlook: Report on the European MedTech CDMO Industry
A return to normalcy has accelerated growth for Europe’s MedTech CDMO industry, but individual companies may be at risk given the increased competitive pressure, logistics disruption,(...)
CDMO MedTech
Events November 30, 2022
Biotech Showcase
We are pleased to attend Biotech Showcase this year, the investor conference for innovators. This will be the 15th edition of the event and it hosts a wide variety of companies, ranging(...)
Biotech Investor Relations Life Sciences
Publications November 10, 2022
How to Choose the Right Analytical Methods
In this article, we focus on the analytical method development around your biologics. Analytical method development is an important component of biologics development and the control(...)
Biotech CDMO Drug Development
News September 27, 2022
AseBio and Alira Health Partner to Foster Market Access for Biotech Startups
Alira Health and AseBio, the Spanish Bioindustry Association, are joining forces to support Spanish biotech companies looking to enter new markets.
Biotech Market Access Startups
Publications September 14, 2022
Critical Quality Attributes for Drug Products
In this article, we will explore the importance of Critical Quality Attributes (CQAs) in the drug development lifecycle and why it is vital that your selected CDMO is capable of addressing them.
Biotech CDMO Drug Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.